Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Trellus Health PLC ( (GB:TRLS) ) just unveiled an update.
Trellus Health plc has issued 32,025,278 new ordinary shares following the conversion of £75,000 of principal under the second tranche of its secured convertible loan notes, continuing the process approved by shareholders earlier this year. The new shares are expected to be admitted to trading on AIM around 23 March 2026, increasing the company’s total shares in issue to 273,637,618 and updating the base for shareholders’ voting-rights calculations under UK disclosure rules.
The enlarged share capital modestly dilutes existing holders but converts a portion of debt into equity, marginally strengthening Trellus Health’s balance sheet while supporting its ongoing development of digital chronic-condition management solutions. The updated voting-rights figure provides a new reference point for investors assessing their notifiable holdings and any future changes in their ownership stakes under regulatory transparency requirements.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on TRLS Stock
According to Spark, TipRanks’ AI Analyst, TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company listed on AIM that provides value-based digital solutions for managing complex chronic conditions through its Trellus Elevate platform, which integrates data analytics, resilience-based methodology, and personalised support. The company initially targets high-cost gastrointestinal diseases such as inflammatory bowel disease, demonstrating substantial reductions in hospitalisations and emergency room visits, and also partners with pharmaceutical companies from clinical trials to commercialisation.
Average Trading Volume: 7,522,740
Technical Sentiment Signal: Sell
Current Market Cap: £785.2K
See more data about TRLS stock on TipRanks’ Stock Analysis page.